Clinical Trials

383 enrolled

Prostatic Neoplasms

NCT04557059 2026-03-13

PRIMORDIUM

693 enrolled

Prostatic Neoplasms

NCT06925737 2026-03-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT04720157 2026-03-11

PSMAddition

1,145 enrolled

Prostatic Neoplasms

NCT04821622 2026-03-11

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT06136650 2026-03-09

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT07028853 2026-03-04

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT04736199 2026-02-27

ARANOTE

669 enrolled 16 charts

Prostatic Neoplasms

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT04689828 2026-02-20

PSMAfore

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT04876651 2026-02-20

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Phase 3 Terminated

16 enrolled

Prostatic Neoplasms

NCT06235099 2026-02-18

Solar-Recur

235 enrolled

Prostatic Neoplasms

NCT06235151 2026-02-17

Solar-Stage

439 enrolled

Prostatic Neoplasms

NCT02257736 2026-02-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT02531516 2026-02-13

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled

Prostatic Neoplasms

NCT01946204 2026-02-02

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-02-02

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT06764485 2026-01-28

rechARge

960 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT06120491 2026-01-21

EvoPAR-PR01

1,800 enrolled

Prostatic Neoplasms

NCT04493853 2026-01-20

CAPItello-281

1,012 enrolled

Prostatic Neoplasms

NCT03767244 2026-01-16

PROTEUS

2,517 enrolled

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT04838613 2025-10-20

GuidePath

190 enrolled 25 charts

Prostatic Neoplasms, Recurrence

NCT04186845 2025-09-22

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

391 enrolled 30 charts

Disease, Prostatic Neoplasms

NCT07052214 2025-09-10

BiPASS

204 enrolled

Prostatic Neoplasms

NCT05590793 2025-09-09

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

195 enrolled 19 charts

Prostatic Neoplasms

NCT05605964 2025-08-17

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

387 enrolled

Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

439 enrolled

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT04742361 2025-07-15

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT04100018 2025-06-12

CheckMate 7DX

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT03072238 2025-06-06

IPATential150

1,101 enrolled 35 charts

Prostatic Neoplasms

NCT04261777 2025-06-03

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

Phase 3 Terminated

172 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT06795178 2025-04-27

KATANA E3M

Phase 3 Withdrawn

Prostatic Neoplasms

NCT06795191 2025-04-27

KATANA E6M

Phase 3 Withdrawn

Prostatic Neoplasms

NCT01220869 2025-04-13

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

110 enrolled 11 charts

Prostatic Neoplasms

NCT02288247 2025-04-08

PRESIDE

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT05004285 2025-03-12

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

398 enrolled

Prostatic Neoplasms

NCT05936658 2025-03-12

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

138 enrolled

Prostatic Neoplasms

NCT04186819 2025-02-26

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

356 enrolled 28 charts

Phase 3 Not yet recruiting

Disease, Prostatic Neoplasms

NCT06837896 2025-02-20

Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

110 enrolled